SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tatyana A. Shamliyan, James R. Johnson, Roderick MacDonald, Aasma Shaukat, Jian-Min Yuan, Robert L. Kane, Timothy J. Wilt, Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection, Journal of General Internal Medicine, 2011, 26, 3, 326

    CrossRef

  2. 2
    Chanunta Hongthanakorn, Anna S.F. Lok, New Pharmacologic Therapies in Chronic Hepatitis B, Gastroenterology Clinics of North America, 2010, 39, 3, 659

    CrossRef

  3. 3
    A. D. ENRIQUEZ, M. S. CAMPBELL, K. R. REDDY, Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis, Alimentary Pharmacology & Therapeutics, 2007, 26, 3
  4. 4
    Robert G. Gish, Stephen Locarnini, Genotyping and Genomic Sequencing in Clinical Practice, Clinics in Liver Disease, 2007, 11, 4, 761

    CrossRef

  5. 5
    Zeki Karasu, Murat Akyildiz, Murat Kilic, Murat Zeytunlu, Unal Aydin, Fatih Tekin, Funda Yilmaz, Tijen Ozacar, Ulus Akarca, Galip Ersoz, Fulya Gunsar, Tankut Ilter, Michael R Lucey, Living donor liver transplantation for hepatitis B cirrhosis, Journal of Gastroenterology and Hepatology, 2007, 22, 12
  6. 6
    Jules L. Dienstag, Looking to the Future: New Agents for Chronic Hepatitis B, The American Journal of Gastroenterology, 2006, 101, S1, S19

    CrossRef

  7. 7
    Yan-Xing Han, Rong Xue, Wei Zhao, Zhen-Xian Zhou, Jian-Nong Li, Hong-Shan Chen, Xiang-Hong Chen, Yan-Ling Wang, Yu-Huan Li, Yin-Wei Wu, Xue-Fu You, Li-Xun Zhao, Jian-Dong Jiang, Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection, Antiviral Research, 2005, 68, 3, 147

    CrossRef

  8. 8
    Robert G. Gish, Current Treatment and Future Directions in the Management of Chronic Hepatitis B Viral Infection, Clinics in Liver Disease, 2005, 9, 4, 541

    CrossRef

  9. 9
    Ching-Lung Lai, Seng Gee Lim, Nathaniel A. Brown, Xiao-Jian Zhou, Deborah M. Lloyd, Yin-Mei Lee, Man-Fung Yuen, George C. Chao, Maureen W. Myers, A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection, Hepatology, 2004, 40, 3
  10. 10
    Vikas Yadav, Chung K Chu, Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study, Bioorganic & Medicinal Chemistry Letters, 2004, 14, 16, 4313

    CrossRef

  11. 11
    A. M. Bozdayi̇, Ö. Uzunalimoğlu, A. R. Türkyi̇lmaz, N. Aslan, O. Sezgin, T. Sahin, G. Bozdayi̇, K. Çi̇nar, S. B. Pai, R. Pai, H. Bozkaya, S. Karayalçi̇n, C. Yurdaydi̇n, R. F. Schinazi, YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine, Journal of Viral Hepatitis, 2003, 10, 4
  12. 12
    RAJKUMAR C GUPTAN, VARSHA THAKUR, SEYED N KAZIM, SHIV K SARIN, Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients, Journal of Gastroenterology and Hepatology, 2002, 17, 7
  13. 13
    A. B. Van Nunen, R. A. De Man, R. A. Heijtink, A. C. T. M. Vossen, S. W. Schalm, Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?, Journal of Viral Hepatitis, 2002, 9, 3
  14. 14
    LMM Wolters, BE Hansen, HGM Niesters, S Zeuzem, SW Schalm, Man. RA de, Lonieke M. M. Wolters, Bettina E. Hansen, Hubert G. M. Niesters, Stefan Zeuzem, Solko W. Schalm, Robert A. De Man, Viral dynamics in chronic hepatitis B patients during lamivudine therapy, Liver, 2002, 22, 2
  15. 15
    Leonieke M. M. Wolters, Bettina E. Hansen, Hubert G. M. Niesters, Robert A. de Man, Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine–famciclovir or lamivudine–ganciclovir, European Journal of Gastroenterology & Hepatology, 2002, 14, 9, 1007

    CrossRef

  16. 16
    J. Hoff, F. Bani-Sadr, M. Gassin, F. Raffi, Evaluation of Chronic Hepatitis B Virus (HBV) Infection in Coinfected Patients Receiving Lamivudine as a Component of Anti-Human Immunodeficiency Virus Regimens, Clinical Infectious Diseases, 2001, 32, 6, 963

    CrossRef

  17. 17
    Teresa Santantonio, Michele Mazzola, Tiziana Iacovazzi, Antonio Miglietta, Angela Guastadisegni, Giuseppe Pastore, Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine, Journal of Hepatology, 2000, 32, 2, 300

    CrossRef

  18. 18
    David R. Musher, Walter G. Wasser, Subodh J. Saggi, High Dose Lamivudine and Hepatitis B, The American Journal of Gastroenterology, 1999, 94, 11, 3372

    CrossRef

  19. 19
    Jules L. Dienstag, Eugene R. Schiff, Teresa L. Wright, Robert P. Perrillo, Hie-Won L. Hann, Zachary Goodman, Lynn Crowther, Lynn D. Condreay, Mary Woessner, Marc Rubin, Nathaniel A. Brown, Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States, New England Journal of Medicine, 1999, 341, 17, 1256

    CrossRef

  20. 20
    Peter M. Rosenberg, Jules L. Dienstag, THERAPY WITH NUCLEOSIDE ANALOGUES FOR HEPATITIS B VIRUS INFECTION, Clinics in Liver Disease, 1999, 3, 2, 349

    CrossRef